Paper Details

  1. Home
  2. Paper Details

Impact of early intervention with alogliptin on coronary plaque regression and stabilization in patients with acute coronary syndromes.

Author: EbinaToshiaki, HibiKiyoshi, IwahashiNoriaki, KikuchiShinnosuke, KimuraKazuo, KosugeMasami, KujiShotaro, MaejimaNobuhiko, MatsuzawaYasushi, NakayamaNaoki, OkadaKozo, TamuraKouichi

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This randomized controlled trial found that alogliptin treatment resulted in significant plaque regression and stabilization in non-culprit lesions in patients with acute coronary syndrome and mild dysglycemia. These findings suggest that early intervention with incretin-based treatments may be beneficial in this patient population.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND AIMS: Anti-atherosclerotic effects of early intervention with dipeptidyl peptidase-4 inhibitors remain poorly defined. METHODS: In a prospective, single-center, randomized trial, 66 patients with acute coronary syndrome (ACS) and mild dysglycemia (HbA1c 6.0 (5.7, 6.3)%, 58% of impair...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.atherosclerosis.2022.09.005

データ提供：米国国立医学図書館（NLM）

Early Alogliptin Intervention: A Potential Ally for Plaque Regression

This study investigates the potential anti-atherosclerotic effects of early intervention with alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with acute coronary syndromes (ACS) and mild dysglycemia. The researchers aimed to assess the impact of early alogliptin treatment on coronary plaque regression and stabilization in this patient population.

Early Intervention: A Promising Strategy for Plaque Management

The study found that early intervention with alogliptin, independent of glycemic and lipid status, resulted in significant plaque regression and stabilization in patients with ACS and mild dysglycemia. This suggests that early treatment with DPP-4 inhibitors may offer a promising strategy for managing coronary plaque progression.

A New Approach to Cardiovascular Health

This research opens up a new avenue for managing cardiovascular disease. The study's findings suggest that early intervention with alogliptin could play a vital role in promoting cardiovascular health, potentially reducing the risk of future cardiovascular events. It's like discovering a hidden path in the desert of cardiovascular disease, leading to a healthier future for patients at risk.

Dr.Camel's Conclusion

This study offers a refreshing perspective on managing cardiovascular health. Like a desert traveler finding a new route to a hidden oasis, researchers have discovered a potential pathway for promoting plaque regression and stabilization. This research holds promise for improving cardiovascular outcomes and paving the way for a healthier future for patients with ACS and mild dysglycemia.

Date :
  1. Date Completed 2022-10-28
  2. Date Revised 2022-12-22
Further Info :

Pubmed ID

36191453

DOI: Digital Object Identifier

10.1016/j.atherosclerosis.2022.09.005

Related Literature

Article Analysis
・Effects of alogliptin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.